Welcome to our dedicated page for Prevail news (Ticker: PRVL), a resource for investors and traders seeking the latest updates and insights on Prevail stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Prevail's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Prevail's position in the market.
Prevail Therapeutics (Nasdaq: PRVL) announced that CEO Asa Abeliovich will speak at the Bank of America Global Research Virtual Health Care Conference on May 12, 2020, at 11:40 a.m. ET. The chat will focus on their innovative AAV-based gene therapies aimed at neurodegenerative diseases.
A live webcast of the event will be available on the company’s website and archived for 90 days. Prevail is developing therapies for Parkinson’s disease with GBA1 mutations, frontotemporal dementia with GRN mutations, and other synucleinopathies.
Summary not available.